Does type 2 diabetes affect the on-treatment levels of direct oral anticoagulants in patients with atrial fibrillation?

Type 2 diabetes (T2D) is connected with higher risk of stroke and systemic embolism in patients with atrial fibrillation (AF). Therefore, T2D patients with AF more often require long-term anticoagulation. Recently, direct oral anticoagulants (DOACs) - direct thrombin inhibitor dabigatran [1], direct factor Xa inhibitors rivaroxaban [2] and apixaban [3] - had been introduced for prevention of stroke and systemic embolism in patients with non-valvular AF (NV-AF). These agents generally offer some advantages, such as consistent and predictable anticoagulation, oral administration with good patient compliance and a good safety profile.
Source: Diabetes Research and Clinical Practice - Category: Endocrinology Authors: Source Type: research